TABLE II.
Bleeding Outcome at 2-Year Follow-Up According to Bleeding Risk Scorea
| Risk group | Patients, No. (%) (N = 1080) | No bleeding, No. (%) (n = 891) | Any bleeding, No. (%) (n = 189) | No major bleeding, No. (%) (n = 1,032) | Major bleeding BARC types 3-5, No. (%) (n = 48) |
|---|---|---|---|---|---|
| HAS-BLED score (mean [SD], 2.23 [0.97]) | |||||
| 0 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 1 | 270 (25) | 241 (89.3) | 29 (10.7) | 267 (98.9) | 3 (1.1) |
| 2 | 405 (37.5) | 342 (84.4) | 63 (15.6) | 393 (97) | 12 (3) |
| 3 | 311 (28.8) | 249 (80.1) | 62 (19.9) | 297 (95.5) | 14 (4.5) |
| 4 | 74 (6.9) | 44 (59.5) | 30 (40.5) | 56 (75.7) | 18 (24.3) |
| 5 | 19 (1.8) | 14 (73.7) | 5 (26.3) | 18 (94.7) | 1 (5.3) |
| 6 | 1 (0.1) | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| P value | <.01 | <.01 | |||
| Low (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Intermediate (1-2) | 675 (62.5) | 583 (86.4) | 92 (13.6) | 660 (97.8) | 15 (2.2) |
| High (≥3) | 405 (37.5) | 308 (76.0) | 97 (24.0) | 372 (91.9) | 33 (8.1) |
| P value | <.01 | <.01 | |||
| HEMORR2HAGES score (mean [SD], 2.05 [1.37]) | |||||
| 0 | 4 (0.4) | 4 (100) | 0 (0) | 4 (100) | 0 (0) |
| 1 | 471 (43.6) | 417 (88.5) | 54 (11.5) | 465 (98.7) | 6 (1.3) |
| 2 | 373 (34.5) | 310 (83.1) | 63 (16.9) | 361 (96.8) | 12 (3.2) |
| 3 | 148 (13.7) | 108 (73.0) | 40 (27.0) | 135 (91.2) | 13 (8.8) |
| 4 | 59 (5.5) | 40 (67.8) | 19 (32.2) | 51 (86.4) | 8 (13.6) |
| 5 | 18 (1.7) | 7 (38.9) | 11 (61.1) | 10 (55.6) | 8 (44.4) |
| 6 | 5 (0.5) | 3 (60.0) | 2 (40.0) | 4 (80.0) | 1 (20.0) |
| 7 | 2 (0.2) | 2 (100) | 0 (0) | 2 (100) | 0 (0) |
| P value | <.01 | <.01 | |||
| Low (0-1) | 475 (44) | 421 (88.6) | 54 (11.4) | 469 (98.7) | 6 (1.3) |
| Intermediate (2-3) | 521 (48.2) | 418 (80.2) | 103 (19.8) | 496 (95.2) | 25 (4.8) |
| High (≥4) | 84 (7.8) | 52 (61.9) | 32 (38.1) | 67 (79.8) | 17 (20.2) |
| P value | <.01 | <.01 | |||
| PARIS score (mean [SD], 4.44 [2.55]) | |||||
| 0 | 21 (1.9) | 20 (95.2) | 1 (4.8) | 21 (100) | 0 (0) |
| 1 | 66 (6.1) | 58 (87.9) | 8 (12.1) | 65 (98.5) | 1 (1.5) |
| 2 | 164 (15.2) | 138 (84.1) | 26 (15.9) | 163 (99.4) | 1 (0.6) |
| 3 | 203 (18.8) | 175 (86.2) | 28 (13.8) | 193 (95.1) | 10 (4.9) |
| 4 | 179 (16.6) | 155 (86.6) | 24 (13.4) | 176 (98.3) | 3 (1.7) |
| 5 | 145 (13.4) | 121 (83.4) | 24 (16.6) | 144 (99.3) | 1 (0.7) |
| 6 | 88 (8.1) | 68 (77.3) | 20 (22.7) | 77 (87.5) | 11 (12.5) |
| 7 | 71 (6.6) | 58 (81.7) | 13 (18.3) | 69 (97.2) | 2 (2.8) |
| 8 | 61 (5.6) | 49 (80.3) | 12 (19.7) | 59 (96.7) | 2 (3.3) |
| 9 | 28 (2.6) | 17 (60.7) | 11 (39.3) | 23 (82.1) | 5 (17.9) |
| 10 | 24 (2.2) | 16 (66.7) | 8 (33.3) | 21 (87.5) | 3 (12.5) |
| 11 | 19 (1.8) | 9 (47.4) | 10 (52.6) | 12 (63.2) | 7 (36.8) |
| 12 | 3 (0.3) | 1 (33.3) | 2 (66.7) | 2 (66.7) | 1 (33.3) |
| 13 | 7 (0.6) | 5 (71.4) | 2 (28.6) | 6 (85.7) | 1 (14.3) |
| 14 | 1 (0.1) | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| P value | <.01 | <.01 | |||
| Low (0-3) | 454 (42.0) | 391 (86.1) | 63 (13.9) | 442 (97.4) | 12 (2.6) |
| Intermediate (4-7) | 483 (44.7) | 402 (83.2) | 81 (16.8) | 466 (96.5) | 17 (3.5) |
| High (≥8) | 143 (13.2) | 98 (68.5) | 45 (31.5) | 124 (86.7) | 19 (13.3) |
| P value | <.01 | <.01 | |||
BARC, Bleeding Academic Research Consortium; HAS-BLED, Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile International Normalized Ratio, Elderly, Drugs/Alcohol; HEMORR2HAGES, Hepatic or Renal Disease, Ethanol Abuse, Malignancy, Older Age, Reduced Platelet Count or Function, Re-Bleeding, Hypertension, Anemia, Genetic Factors, Excessive Fall Risk and Stroke; PARIS, Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients.
P < .05 was considered statistically significant.
a
Percentages in table may not total 100.0% due to rounding.